TY - JOUR
T1 - High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas
AU - Kacinski, Barry M.
AU - Carter, Darryl
AU - Mittal, Khushbakhat
AU - Kohorn, Ernest I.
AU - Bloodgood, R. Shaeffer
AU - Donahue, John
AU - Donofrio, Lisa
AU - Edwards, Rob
AU - Schwartz, Peter E.
AU - Chambers, Joseph T.
AU - Chambers, Setsuko K.
N1 - Funding Information:
Endometrial adenomas and adenocarcinomas present a spectrum of pathologic entities which includes benign cystic hyperplasias, atypical hyperplasias of low malignant potential to well, moderately-well and poorly-differentiated invasive adenocarcinomas. Other less common histologies (mixed mullerian tumors, etc) are also observed. Clinical presentations range from small lesions confined to the superficial endometrium to lesions which have spread to the uterine cervix and/or the myometrium to aggressively malignant neoplasms with spread to adjacent pelvic structures, pelvic lymph nodes and distant visceral sites. At least for adenocarcinomas, clinical extent of disease and histologic grade at presentation both correlate very strongly with outcome.g,13,22 Acknowledgement-This research was supported by American Cancer Society Research Grant CD 262 and a Swebilius Foundation Research Award to Dr. Barry M. Kacinski. Tissue retrieval and storage was supported by the National Institutes of Health Core Research Grant Award to the Yale Comprehensive Cancer Center. Accepted for publication 2 1 April 1988.
PY - 1988/10
Y1 - 1988/10
N2 - Six micron paraffin sections of paraformaldehyde-fixed endometrial currettings of 21 benign and neoplastic endometrial specimens were assayed for tumor cell-specific oncogene expression by in situ hybridization with probes for six oncogenes, beta-actin, and the E. coli plasmid pBR322. In the benign hyperplasias and invasive adenocarcinomas, multiple oncogenes, including erbB, fms, c-myc, and Ki-ras were expressed at significant levels. For the adenocarcinomas, statistical analysis demonstrated that high levels of expression of fms-complementary mRNA correlated strongly with clinicopathologic features (high FIGO histologic grade, high FIGO clinical stage, deep myometrial penetration) predictive of aggressive clinical behavior and poor outcome. The authors discuss the role which M-CSF receptor (the fms gene product) and locally-produced M-CSF may play in the development of the observed aggressively-malignant phenotypes. They also propose that pre-hysterectomy assay of fms gene expression in endometrial currettings in FIGO Stage I patients might be clinically useful to help identify preoperatively those patients with deep myometrial penetration or other locoregional spread.
AB - Six micron paraffin sections of paraformaldehyde-fixed endometrial currettings of 21 benign and neoplastic endometrial specimens were assayed for tumor cell-specific oncogene expression by in situ hybridization with probes for six oncogenes, beta-actin, and the E. coli plasmid pBR322. In the benign hyperplasias and invasive adenocarcinomas, multiple oncogenes, including erbB, fms, c-myc, and Ki-ras were expressed at significant levels. For the adenocarcinomas, statistical analysis demonstrated that high levels of expression of fms-complementary mRNA correlated strongly with clinicopathologic features (high FIGO histologic grade, high FIGO clinical stage, deep myometrial penetration) predictive of aggressive clinical behavior and poor outcome. The authors discuss the role which M-CSF receptor (the fms gene product) and locally-produced M-CSF may play in the development of the observed aggressively-malignant phenotypes. They also propose that pre-hysterectomy assay of fms gene expression in endometrial currettings in FIGO Stage I patients might be clinically useful to help identify preoperatively those patients with deep myometrial penetration or other locoregional spread.
KW - CSF-1 receptor
KW - Endometrial carcinoma
KW - FMS oncogene
KW - Growth factor receptors
KW - In situ hybridization
KW - Tumor/stromal interactions
UR - http://www.scopus.com/inward/record.url?scp=0023767589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023767589&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(88)90113-7
DO - 10.1016/0360-3016(88)90113-7
M3 - Article
C2 - 3182322
AN - SCOPUS:0023767589
SN - 0360-3016
VL - 15
SP - 823
EP - 829
JO - International Journal of Radiation Oncology, Biology, Physics
JF - International Journal of Radiation Oncology, Biology, Physics
IS - 4
ER -